| Title: |
P583 Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn’s disease: results from a large Italian cohort study |
| Authors: |
Mocci, G; Cuomo, A; Allegretta, L; Aragona, G; Colucci, R; Della Valle, N; Ferronato, A; Forti, G; Gaiani, F; Graziani, M G; Lorenzetti, R; Luzza, F; Penna, A; Pica, R; Piergallini, S; Rodinò, S; Scarcelli, A; Zampaletta, C; Cicerone, C; Cocco, A; De Angelis, G; Donnarumma, L; Pranzo, G; Franceschi, M; Gallina, S; Grasso, G; Larussa, T; Luppino, I; Faggiani, R; Fanigliulo, L; Pagnini, C; Perazzo, P; Sacco, R; Sebkova, L; Serio, M E; De Monti, A; Picchio, M; Elisei, W; Maconi, G; Tursi, A |
| Source: |
Journal of Crohn's and Colitis ; volume 15, issue Supplement_1, page S536-S537 ; ISSN 1873-9946 1876-4479 |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2021 |
| Description: |
Background Ustekinumab (UST) is an anti-IL12/23 antibody for the treatment of Crohn’s Disease (CD). The aim of this study was to compare the efficacy and safety of UST in a large population-based cohort of CD patients who failed previous treatment with other biologics Methods 194 CD patients (108 males and 86 females, mean age 48 years (range 38–58 years) were retrospectively reviewed. 147 patients were already treated with anti-TNFα (75.8%), and 47 (24.2%) patients were already treated with anti-TNFα and vedolizumab. Concomitant treatment with steroids was present in 177 (91.2%) patients Results At week 12, clinical remission was achieved in 146 (75.2%) patients. After a mean follow-up of 6 months, clinical remission was maintained in 135 (69.6%) patients; at that time, mucosal healing was assessed in 62 (31.9%) patients, and it was achieved in 33 (53.2) patients. Three (1.5%) patients were submitted to surgery. Steroid-free remission was achieved in 115 (59.3%) patients. Both serum C-Reactive Protein and Fecal Calprotectin (FC) levels were significantly reduced with respect to baseline levels during follow-up. A logistic regression, UST therapy as thirdline therapy (after both anti-TNFα and vedolizumab), FC >200 μg/g, and HBI ≥8 were significantly associated with lack of remission. Adverse events occurred in 5 (2.6%) patients, and four of them required suspension of treatment Conclusion Ustekinumab seemed to be really effective and safe in CD patients unresponsive to other biologic treatments, especially when used as second-line treatment. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/ecco-jcc/jjab076.704 |
| Availability: |
https://doi.org/10.1093/ecco-jcc/jjab076.704; http://academic.oup.com/ecco-jcc/article-pdf/15/Supplement_1/S536/38319383/jjab076.704.pdf |
| Rights: |
https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model |
| Accession Number: |
edsbas.F741F086 |
| Database: |
BASE |